Founded in 2006, with registered capital of 20 million yuan, Sichuan Sunheal is committed to research, development, distribution of pharmaceutical product as well as the agency for overseas pharmaceutical companies. At present, the company system is running effectively with its sales network covering 32 provinces, municipalities and autonomous regions of China.
Sichuan Qingmu Pharmaceutical Co., Ltd. is mainly engaged in research, production and marketing of APIs, CMO/CDMO business of APIs & advanced intermediates is also included in our business scope. Qingmu was established in 2011, with more than 30% of staffs in R&D unit, 16 products are commercialized till now. Our facility is fully designed and operated as per EU/US/Japan GMP and EHS requirements, QC lab is equipped with HPLC, GC and ICP-MS, GC-MS, Malvern particle sizer, XRD, TGA, DSC, etc., which leads to GMP certificates for 10 APIs, 3 J-MFs, 1 USDMF, 2 USVMF and 1 CEP, and more certificates are on the way.
Xizang Runhe Pharmaceutical Co., Ltd., a full subsidiary of Easton Biopharma, is established in 2015 with a registered capital of CNY 12 million. Xizang Runhe Pharma obtained Good Supply Practice (GSP) certification in April 2016 and mainly provides distribution of drug products for domestic customers.
Chengdu Shuode Pharmaceutical Co., Ltd., a full subsidiary of Easton Biopharma, is established in 2016 with a registered capital of CNY 100 million. It is in the process of construction.
Established in 2018 with a registered capital of CNY80 million, Chengdu Unovel Pharmaceutical Co., Ltd. is committed to the research and development of biological drugs.